Screening for Colorectal Cancer after the NordICC trial- Need to Re-consider?
February 1st @ 1:00 pm - 1:50 pm
Department of Epidemiology Seminar Series
Michael Bretthauer, MD PhD
Professor of Medicine, University of Oslo
and the Arctic University of Norway (UiT) and
Oslo University Hospital, Norway
For two decades, colonoscopy has been the number one screening test for colorectal cancer in the United States. Colonoscopy screening has been promoted to reduce incidence and death of colorectal cancer by up to 88%. However, randomized trial evidence to proof these claims have been lacking.
On October 9, 2022, the results of the Nordic-European Initiative on Colorectal Cancer (NordICC), trial was published in the New England Journal of Medicine.
NordICC is a pragmatic randomized trial involving nearly 85,000 men and women in Europe who were randomly assigned to screening colonoscopy or usual care (no screening).
The NordICC trial received widespread media attention worldwide and has sparked engaged discussions in academia, clinical medicine, and the public about the effectiveness of colonoscopy screening for colorectal cancer.
In this talk, Michael Bretthauer, the lead investigator of the NordICC trial, will discuss the implications of the new trial results for colorectal cancer screening in the United States and elsewhere.